SWITCHED ON
The daily technology series nobody asked for but everyone needed
Life, Engineered: Synthetic Biology and the Designer Microbe Revolution
Scientists are programming living cells to produce medicines, materials, and fuels. The same tools that could end disease could also be used to engineer pathogens. Welcome to the most powerful and least discussed technology of our era.
Every previous industrial revolution used physical forces to transform materials — heat, pressure, mechanical force. Synthetic biology uses the logic of life itself. Cells are the factories. DNA is the code. The products range from life-saving medicines to materials with properties nature never evolved, and the dual-use implications are the most serious of any technology in this series.
Yesterday we measured ourselves into mild anxiety — wearables, continuous glucose monitors, orthosomnia, the engagement-optimised health dashboard, and the important distinction between information that helps you make a decision and information that simply makes you aware of something you cannot meaningfully act on. Today we are going somewhere considerably more consequential and considerably less discussed in polite company. Synthetic biology: the engineering of living organisms to perform functions they would not naturally perform, at scales and with precision that were science fiction twenty years ago and are daily operational reality now. This is a technology that is already producing medicines, materials, and food ingredients used by millions of people who have no idea biology was involved. It is also a technology whose dual-use implications — the same knowledge and tools that enable beneficial applications can enable catastrophic ones — make it arguably the most governance-critical field in science. We need to talk about it properly.
01 — What Synthetic Biology Actually Is
Biology is information technology. This is not a metaphor. DNA is a digital code — a four-letter alphabet encoding instructions that cells execute with extraordinary fidelity. Synthetic biology is the discipline of reading, writing, and editing that code with engineering precision: designing novel genetic sequences, synthesising them chemically, inserting them into living organisms, and coaxing those organisms to produce outputs — proteins, chemicals, materials — that the original organism would not naturally make.
The enabling technologies have converged dramatically over the past two decades. DNA synthesis — the ability to chemically manufacture custom DNA sequences — has fallen in cost by several orders of magnitude, following a trajectory similar to semiconductor cost reduction. Gene sequencing has fallen even faster. CRISPR, which we covered in Season One's genetics episode, made precise genome editing accessible to any reasonably equipped molecular biology laboratory. Computational tools for predicting how proteins fold from genetic sequences — AlphaFold being the landmark example — have transformed what is possible in protein design. The combination of cheap synthesis, accessible editing, and powerful computational design has created a field that can prototype biological systems with an iterative speed that was previously unimaginable.
The cost of synthesising a thousand base pairs of DNA has fallen from roughly $10,000 in 2000 to under $0.10 today. The cost of reading a human genome has fallen from $3 billion to under $200. These are not incremental improvements. They are the kind of cost reductions that create entirely new industries and make previously theoretical applications routine.
02 — What Is Already Being Made
The products of synthetic biology are already embedded in daily life in ways that most consumers are unaware of, which is partly a communication failure and partly a reflection of how invisible supply chains are to end users.
Insulin — the hormone that keeps diabetics alive — is produced almost entirely through synthetic biology. The human insulin gene is inserted into bacteria or yeast, which produce the protein at industrial scale. This replaced the previous method of extracting insulin from pig and cow pancreases, and it is unambiguously better in every measurable respect. Artemisinin, the most effective antimalarial drug, was previously extracted from the sweet wormwood plant at considerable cost and with significant supply variability. Amyris, a synthetic biology company, engineered yeast to produce it, dramatically stabilising supply and reducing cost for a medicine that saves hundreds of thousands of lives annually.
Ginkgo Bioworks, the synthetic biology platform company that went public in 2021, works with clients across pharmaceuticals, food ingredients, agriculture, and industrial materials, engineering microbes to produce everything from fragrance compounds to nitrogen-fixing bacteria that could reduce agricultural fertiliser demand. Modern Meadow has produced leather-like materials from yeast. Bolt Threads produced spider silk — a material with extraordinary strength-to-weight properties that spiders produce but that cannot be farmed at scale — by engineering yeast to produce the silk protein. The breadth of applications is extraordinary, and the industrial pipeline is substantially larger than public awareness of the field would suggest.
03 — The Food System Transformation
Synthetic biology's most immediate consumer-facing impact may be in the food system, where several distinct but related technologies are converging to change how proteins and other food ingredients are produced.
Precision fermentation — using engineered microorganisms to produce specific food proteins — is already producing animal proteins without animals. Perfect Day uses fungi to produce whey protein molecularly identical to that from cows, used in ice cream and other dairy products. Remilk and Change Foods are pursuing similar approaches. The proteins produced are structurally identical to their animal-derived equivalents, produced without the land use, water use, greenhouse gas emissions, or antibiotic use associated with conventional dairy and animal agriculture. They are also substantially more expensive than conventional alternatives at current production scales, with the commercial case depending on cost reduction through scale that has not yet fully materialised.
Cultivated meat — growing animal muscle tissue from cells without slaughtering animals — is a related but distinct technology that has received regulatory approval in Singapore and the US for limited commercial sale, though the economic path to mass-market price parity with conventional meat remains substantially longer than early advocates projected. The technology works at small scale. The manufacturing challenge of producing it at the scale and cost required to displace meaningful fractions of the conventional meat market is genuinely difficult, involving bioreactor engineering, growth media cost reduction, and texture and sensory challenges that remain partially unsolved.
04 — The Biosecurity Problem
The dual-use nature of synthetic biology is the conversation that the field's enthusiasts would prefer to have quietly and its critics would prefer to have loudly, and the truth is that both positions are partially right in ways that are uncomfortable to hold simultaneously.
The tools of synthetic biology — DNA synthesis, genome editing, protein design — are genuinely dual-use in a way that has few parallels in the history of technology. The same knowledge and equipment that enables the engineering of beneficial organisms enables the engineering of harmful ones. The Biological Weapons Convention of 1972 prohibits the development, production, and stockpiling of biological weapons, but it has no verification mechanism — there is no equivalent of nuclear inspections or chemical weapons destruction programs. The treaty relies entirely on national compliance declarations that cannot be independently verified.
The concern is not primarily about state bioweapons programs, though these exist and are a serious security concern that multiple intelligence agencies track actively. The more novel concern is about the democratisation of the tools. A DNA synthesiser that costs tens of thousands of dollars — accessible to university laboratories and small companies — can produce custom genetic sequences that were previously available only to state actors. The knowledge required to design a dangerous pathogen, while still substantially beyond what most researchers possess, is becoming less scarce as AI-assisted protein design and expanding biological databases lower the expertise threshold for sophisticated genetic engineering. The biosecurity community has been raising these concerns for years. The governance response has been fragmented, slow, and inadequately resourced relative to the pace of technological development.
The hardest biosecurity problem is not stopping a state from developing biological weapons — that is a known and tractable arms control challenge. The hardest problem is preventing a small group of technically competent individuals from using commercially available tools and published scientific literature to engineer something harmful. That problem does not have a clean solution, and the tools that make it possible are becoming more accessible every year.
05 — Governing What You Cannot See
Synthetic biology governance is attempting to apply regulatory frameworks designed for twentieth-century biotechnology — GMO crop approvals, pharmaceutical clinical trials, biosafety level laboratory requirements — to a field that has fundamentally changed in its accessibility, its pace, and its scope of application.
The most practical near-term governance tool is screening of DNA synthesis orders — requiring DNA synthesis companies to check requested sequences against databases of dangerous pathogens and refuse to synthesise sequences that match. The major commercial synthesis companies have implemented screening programs, and an international consortium has developed harmonised screening standards. This is genuinely useful and genuinely incomplete: it raises the barrier to accessing dangerous sequences through legitimate commercial channels while doing nothing about sequences assembled from shorter non-flagged fragments, synthesis capacity in jurisdictions with no screening requirements, or capabilities developed in-house by well-resourced state or non-state actors.
The longer-term governance challenge is one this series has encountered repeatedly: the technology develops faster than the institutions designed to oversee it. The International Biosecurity and Biosafety Initiative for Science, various national biosecurity advisory bodies, and academic working groups are producing thoughtful frameworks and policy recommendations. The pace at which those recommendations translate into binding international obligations and adequately funded enforcement is considerably slower than the pace at which the technology continues to develop. Synthetic biology will likely produce some of the most beneficial technologies of the next several decades. Whether it produces any of the worst depends significantly on whether the governance conversation happening in committee rooms and academic conferences moves, somewhat urgently, into international treaty frameworks with teeth.
Tomorrow we are staying in the frontier science space but heading somewhere that requires no biology background whatsoever — spatial computing and the blending of digital and physical reality. What Apple Vision Pro's launch actually revealed about the state of the technology, where spatial computing goes from here, and whether the interface paradigm it represents is the future or a very expensive detour. See you then.
Switched On is a daily technology series covering the ideas, systems, and arguments shaping the digital world. Opinionated. Witty. Occasionally wrong. Always worth the argument.
